NBC Producer Slashed Her Toxic Brain Plaque From 86 to 4 After Shocking Alzheimer’s Test: Inside Susan Kroll’s Reversal Strategy

When veteran NBC News producer Susan Kroll learned that toxic amyloid plaque was accumulating in her brain, she wondered if she would soon need round-the-clock memory care. Instead, a targeted medical regimen and rigorous lifestyle overhaul dropped her brain amyloid score from 86 down to just 4, prompting her radiologist to document that the issue had resolved.

The 58-year-old producer brought her deeply personal story directly to national television on the TODAY show, flanked by reporting from senior national correspondent Kate Snow. Co-anchor Savannah Guthrie introduced Kroll as “very dear to us,” while Craig Melvin framed her breakthrough as genuine hopeful news in the broader medical battle against neurodegenerative disease.

Kroll’s journey did not start in an infusion suite. It began when she stepped up to care for her ailing mother.

Segment on TODAY Show featuring Susan Kroll.

A Family Warning Sign Sparks Early Detection

Watching her mother navigate a debilitating Alzheimer’s diagnosis spurred Kroll into immediate investigative mode. While trying to understand the trajectory of her mother’s illness, she elected to undergo medical screening to assess her own personal profile.

“I found out my mom had Alzheimer’s and I went down this path to try to help her and to figure out what this disease was about. I started to realize that it’s this journey about me as well.”

Screening tests uncovered positive biomarkers, confirming that Kroll carried an elevated genetic Alzheimer’s risk. Doctors located significant deposits of amyloid plaque—the misfolded protein long associated with cognitive decline and neural damage.

The discovery forced Kroll to confront subtle memory slips she had previously brushed aside. She wondered whether her occasional inability to find words stemmed from normal aging or the hormonal shifts of menopause, which frequently triggers brain fog.

TODAY segment documenting Susan Kroll and her family history.

Challenging the Inevitability Myth

A widespread misconception suggests that a genetic predisposition to dementia functions as an unalterable life sentence. Many assume that once biomarkers appear, patients can only watch and wait for symptoms to worsen.

Clinical data directly challenges that fatalistic view. Research indicates that up to 45% of dementia cases can potentially be delayed or prevented by systematically targeting modifiable risk factors, including obesity, high cholesterol, and social isolation.

Faced with those numbers, Kroll treated her daily routine as an active medical intervention. She refused to passively accept cognitive deterioration.

The Daily Protocol: How Susan Kroll Took Control

Kroll was already active and health-conscious, but facing a tangible biomarker forced her to elevate every single habit. She approached her health plan with the precision of a breaking news room.

Nutritional Overhaul and Targeted Exercise

To directly counter systemic inflammation and support brain health, Kroll restructured her weekly intake from the ground up:

• Eliminated completely: Artificial sweeteners and excessive sugar.
• Strictly limited: Fried items, ultra-processed meals, red meat, cheese, and alcohol.
• Daily staples: Leafy greens, intact whole grains, colorful vegetables, and fresh fruit.
• Weekly power foods: Multiple weekly servings of cold-water fish, walnuts, almonds, avocados, and berries.
• Cardiovascular training: 45 to 60 minutes of intensive cardio sessions three to four days per week.
• Structural strength & rest: Added structured resistance training and shifted her nightly bedtime earlier to maximize restorative sleep.

Lifestyle modification served as one half of the equation. The other half came from advanced clinical pharmacology.

Segment on TODAY Show featuring Susan Kroll.

Clinical Breakthrough: The Infusion Regimen

Alongside her strict daily habits, Kroll began treatment with Kisunla, an anti-amyloid infusion therapy approved by the FDA in 2024. The drug specifically works to bind and clear amyloid plaque clusters from neural tissue.

After completing six targeted infusion cycles, she entered an imaging scanner to review her clinical progress. The follow-up scan revealed an astonishing outcome.

“In May this year, I had another scan to determine my progress. I went from a score of 86 to a 4. The radiologist wrote in the notes, ‘The amyloid issue has resolved.'”

The drastic clearance proved that early detection combined with modern clinical therapy can alter the biological trajectory of the disease before extensive cognitive damage takes root.

💬 Kroll hopes her vulnerability spurs others to explore preventive screenings rather than letting fear keep them in the dark.

✨ Her journey proves that uncovering a high Alzheimer’s risk does not mean surrendering your future.

📱 Medical advances and aggressive lifestyle changes offer practical pathways to protect long-term brain health.

👇 Have you or a loved one explored genetic testing for cognitive health? Share your thoughts and experiences in the comments below.